Brian Miller

[SentienBiotech @SentienBiotech]

Read @SentienBiotech's new publication with data from our first Ph I/II study of SBI-101 in subjects with AKI! Data supports the therapeutic hypothesis that ex vivo delivery of MSC-secreted factors leads to immunomodulation & reprogramming of immune cells https://t.co/tXcwGtjFPQ

[Mesenchymal Cell News @MesenchymalCell]

A Phase Ib study evaluated the pharmacological effects of ex vivo #MesenchymalStemCell immunotherapy in patients with acute #KidneyInjury and underlying systemic inflammation.

🔓 https://t.co/AmMmT1aVmR

[SentienBiotech @SentienBiotech]

@SentienBiotech Partners with @BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis, Including from #COVID19 https://t.co/Mo0yPOs9Hb via @PRWeb

[SentienBiotech @SentienBiotech]

Check out @SentienBiotech's upcoming presentations at #ISCT2021! Dr. Rita Barcia, VP of R&D, will share early data from our Ph1/2 trial of SBI-101 for the treatment of severe #COVID19 & will be featured during an interview session on ISCT TV on 5/26! #celltherapy #MSC @ISCTglobal

[SentienBiotech @SentienBiotech]

Register for this webinar on Wed 4/28 with @SentienBiotech VP of R&D, Dr. Rita Barcia, discussing considerations for #MSC product and process development through clinical cGMP manufacturing, alongside other distinguished panelists! @RoosterBio @jan_nolta

[SentienBiotech @SentienBiotech]

@SentienBiotech Completes Enrollment of First Cohort in Ph 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19 https://t.co/3WF254ZGso via @PRWeb #COVID19 #celltherapy #MSC

[SentienBiotech @SentienBiotech]

@SentienBiotech Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19 https://t.co/oOxZ93Uggb via @PRWeb @ChristosArgyrop @NephCrit_NM @gtrejoleal #COVID19 #celltherapy #MSC

[SentienBiotech @SentienBiotech]

Check out @SentienBiotech CEO Brian Miller's presentation from the @alliancerm Cell & Gene Meeting on the Mesa!

https://t.co/gLKj8YyuZc

[SentienBiotech @SentienBiotech]

@SentienBiotech Announces Open IND in Ph 1/2 Trial of SBI-101 for Patients with COVID-19! #COVID19 #celltherapy

https://t.co/P9XuLbY16U

[SentienBiotech @SentienBiotech]

Check out @SentienBiotech's publication in Nature @SciReports on our MSC bioreactor platform! https://t.co/c3hR1h65nG #MSC #CellTherapy

[Cell Mentor @CellMentor]

Small biotechs and startups are pivoting to address the COVID-19 pandemic.

In our latest blog post, @labcentral co-founder @JFruehauf interviews execs from @AldatuBio, @Vaxess, @SentienBiotech, and @Affinivax about the changes they're facing.

https://t.co/szZ9EG9gqQ

[SentienBiotech @SentienBiotech]

@SentienBiotech Names Richard Ganz as Executive Chairman https://t.co/Nqd63G5NZh via @PRWeb

[Johannes Fruehauf🇺🇦 @JFruehauf]

Next #COVIDbuster: @SentienBiotech is amending their #clinicaltrial 2 include #ARDS patients w #COVID19.

Their mesenchymal stem cell device #SBI101 has promise to treat patients with #CytokineStorm, the severe dysbalance often seen in late disease.🤞
@labcentral @MissionBioCap

[Cell & Gene Therapy - Informa Connect @CellTherapyIC]

Chris Gemmiti, VP of Operations @SentienBiotech discusses the highs and lows of mesenchymal #StemCells and whether their peak is yet to come. Read more: https://t.co/DtqzuwUlFc

[SentienBiotech @SentienBiotech]

@SentienBiotech CEO Brian Miller to present at @alliancerm Cell & Gene Meeting on the Mesa on October 4 at 1:15pm #mesa17 #celltherapy #MSC

[Brian Miller @blkmiller]

Congrats, FORMA! https://t.co/CKk3OFTB37

[SentienBiotech @SentienBiotech]

At Stem Cell Summit, CEO @blkmiller announced an active IND for SBI-101 in patients with acute kidney injury! https://t.co/FEHxLHGA9E

[Brian Miller @blkmiller]

Thanks! RT @JFruehauf: Congratulations @labcentral resident #Sentien: Announces $12M Series A financing today: https://t.co/xEPJdOO1m5